Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism.

Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, Chen GZ, Boggon TJ, Lonial S, Fu H, Khuri FR, Kang S, Chen J.

Mol Cell. 2011 Dec 23;44(6):864-77. doi: 10.1016/j.molcel.2011.10.015.


Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth.

Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, Xie J, Gu TL, Polakiewicz RD, Roesel JL, Boggon TJ, Khuri FR, Gilliland DG, Cantley LC, Kaufman J, Chen J.

Sci Signal. 2009 Nov 17;2(97):ra73. doi: 10.1126/scisignal.2000431.


Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation.

Kang S, Elf S, Dong S, Hitosugi T, Lythgoe K, Guo A, Ruan H, Lonial S, Khoury HJ, Williams IR, Lee BH, Roesel JL, Karsenty G, Hanauer A, Taunton J, Boggon TJ, Gu TL, Chen J.

Mol Cell Biol. 2009 Apr;29(8):2105-17. doi: 10.1128/MCB.00998-08. Epub 2009 Feb 17.


Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.

Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S.

J Clin Oncol. 1998 Sep;16(9):3129-36.


pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs.

Leroux JC, Cozens RM, Roesel JL, Galli B, Doelker E, Gurny R.

Pharm Res. 1996 Mar;13(3):485-7. No abstract available.


Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice.

Leroux JC, Cozens R, Roesel JL, Galli B, Kubel F, Doelker E, Gurny R.

J Pharm Sci. 1995 Dec;84(12):1387-91.


CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.

Alteri E, Bold G, Cozens R, Faessler A, Klimkait T, Lang M, Lazdins J, Poncioni B, Roesel JL, Schneider P, et al.

Antimicrob Agents Chemother. 1993 Oct;37(10):2087-92.


Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.

Geissler JF, Roesel JL, Meyer T, Trinks UP, Traxler P, Lydon NB.

Cancer Res. 1992 Aug 15;52(16):4492-8.


Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase.

Traxler PM, Wacker O, Bach HL, Geissler JF, Kump W, Meyer T, Regenass U, Roesel JL, Lydon N.

J Med Chem. 1991 Aug;34(8):2328-37.


Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.

Geissler JF, Traxler P, Regenass U, Murray BJ, Roesel JL, Meyer T, McGlynn E, Storni A, Lydon NB.

J Biol Chem. 1990 Dec 25;265(36):22255-61.

Supplemental Content

Loading ...
Support Center